Primary Lateral Sclerosis (PLS)

Primary Lateral Sclerosis (PLS) is a rare, slow-progressing neurodegenerative disease that selectively affects the upper motor neurons (UMN). Unlike Amyotrophic Lateral Sclerosis (ALS), PLS does not affect lower motor neurons, resulting in a much slower rate of progression.

• Presentation: Key diagnostic signs.
  • *Lower Limb Spasticity:* Gradually increasing stiffness, tightness, and weakness in the legs. This causes balance impairments, frequent tripping, and a spastic, stiff-legged gait.
  • *Bulbar Symptoms:* Progressive spastic dysarthria (slow, slurred, effortful speech), dysphagia (difficulty swallowing), and pseudobulbar affect (uncontrolled laughing or crying).
  • *Upper Limb Stiffness:* Clumsiness and stiffness in the hands, impacting fine motor tasks like writing or buttoning shirts.
  • *Hyperreflexia:* Significantly increased deep tendon reflexes and positive Babinski signs, without muscle wasting or fasciculations (twitches).

Diagnosis requires clinical evidence of isolated UMN dysfunction, brain/spinal cord MRI to exclude mimickers, and electromyography (EMG) to rule out lower motor neuron disease.

• Diagnostic Markers: Key criteria.
  • Brain & Spine MRI: Often demonstrates progressive atrophy of the motor cortex, specifically the **precentral gyrus**. MRI of the spine excludes compressive myelopathies.
  • Electromyography (EMG): Must show no evidence of active denervation (e.g. fibrillation potentials, positive sharp waves) in bulbar, cervical, thoracic, or lumbosacral regions, confirming the absence of lower motor neuron involvement.
  • Observation Period: A definitive diagnosis of PLS usually requires at least 3 to 4 years of continuous clinical tracking to ensure lower motor neuron symptoms do not develop (which would reclassify the diagnosis to ALS).

Pathophysiology of UMN Degeneration

PLS selectively targets the motor neurons originating in the cerebral cortex:

• Betz Cell Degeneration: The disease is characterized by the loss of giant pyramidal cells (**Betz cells**) in layer V of the primary motor cortex.
• Retrograde Axonal Loss: De-innervation leads to degeneration of the corticospinal (projecting to the spinal cord) and corticobulbar (projecting to the brainstem motor nuclei) pathways, removing the normal inhibitory control over motor reflex loops.
• Absence of Lower Motor Neuron Pathology: The anterior horn cells in the spinal cord and cranial motor nuclei in the brainstem remain structurally intact, preserving the motor unit connections to skeletal muscles.

Management is purely symptomatic, focused on reducing spasticity, preserving range of motion, and supporting speech and swallowing functions.

Spasticity Interventions

• Oral Muscle Relaxants: GABA agonists such as **Baclofen** (10-80 mg daily in divided doses) and **Tizanidine** (4-24 mg daily) are used as first-line agents to decrease muscle tone and spasms.
• Intrathecal Baclofen Pump (ITB): In patients with severe, refractory leg spasticity, a surgically implanted pump delivering Baclofen directly to the spinal cord space is used to achieve higher local concentrations with fewer systemic side effects.

Rehabilitative & Speech Therapies

• Physical & Occupational Therapy: Daily passive stretching prevents muscle contractures and preserves joint mobility, while assistive devices (canes, walkers, wheelchair adaptations) support safe movement.
• Speech & Language Therapy: Deployed early to assist with spastic dysarthria. Speech therapists help select Augmentative and Alternative Communication (AAC) devices when verbal speech becomes severely impaired.

Clinical trials are currently evaluating novel neuroprotective compounds, UMN cell therapies, and home-based speech monitoring technologies.

If you have recently been diagnosed with Primary Lateral Sclerosis, establish these clinical care pathways:

1. Establish Care with an ALS/Neuromuscular Center: Access multidisciplinary clinics containing neurologists, physical therapists, and speech therapists.
2. Schedule Baseline Speech & Swallowing Tests: Establish your baseline parameters to track future bulbar involvement.
3. Begin First-Line Spasticity Therapy: Work with your neurologist to find an optimal dose of Baclofen or Tizanidine.
4. Plan Regular EMG Follow-ups: Schedule yearly EMGs for the first 3-4 years to rule out lower motor neuron involvement (ALS).

Q: How does PLS differ from ALS?
A: Both are motor neuron diseases. However, ALS affects both upper motor neurons (brain) and lower motor neurons (spinal cord), leading to rapid muscle wasting, weakness, and a life expectancy of 3-5 years. PLS selectively affects upper motor neurons, causing muscle stiffness and spasticity without muscle wasting, and has a normal or near-normal life expectancy.

Q: Can PLS turn into ALS?
A: Yes. In some cases, patients initially diagnosed with PLS go on to develop lower motor neuron symptoms (muscle wasting, twitches) years later, resulting in a re-diagnosis of ALS. This transition most commonly occurs within the first 3 to 4 years after symptom onset.